These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 27477337)

  • 1. Naltrexone/Bupropion extended release-induced weight loss is independent of nausea in subjects without diabetes.
    Hong K; Herrmann K; Dybala C; Halseth AE; Lam H; Foreyt JP
    Clin Obes; 2016 Oct; 6(5):305-12. PubMed ID: 27477337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II).
    Apovian CM; Aronne L; Rubino D; Still C; Wyatt H; Burns C; Kim D; Dunayevich E;
    Obesity (Silver Spring); 2013 May; 21(5):935-43. PubMed ID: 23408728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Psychiatric adverse events and effects on mood with prolonged-release naltrexone/bupropion combination therapy: a pooled analysis.
    Pi-Sunyer X; Apovian CM; McElroy SL; Dunayevich E; Acevedo LM; Greenway FL
    Int J Obes (Lond); 2019 Oct; 43(10):2085-2094. PubMed ID: 30664661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Naltrexone ER/Bupropion ER: A Review in Obesity Management.
    Greig SL; Keating GM
    Drugs; 2015 Jul; 75(11):1269-80. PubMed ID: 26105116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Greenway FL; Fujioka K; Plodkowski RA; Mudaliar S; Guttadauria M; Erickson J; Kim DD; Dunayevich E;
    Lancet; 2010 Aug; 376(9741):595-605. PubMed ID: 20673995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extended-release naltrexone/bupropion is safe and effective among subjects with type 2 diabetes already taking incretin agents: a post-hoc analysis of the LIGHT trial.
    Wharton S; Yin P; Burrows M; Gould E; Blavignac J; Christensen RAG; Kamran E; Camacho F; Barakat M
    Int J Obes (Lond); 2021 Aug; 45(8):1687-1695. PubMed ID: 34083744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo.
    Greenway FL; Dunayevich E; Tollefson G; Erickson J; Guttadauria M; Fujioka K; Cowley MA;
    J Clin Endocrinol Metab; 2009 Dec; 94(12):4898-906. PubMed ID: 19846734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Method-of-use study of naltrexone sustained release (SR)/bupropion SR on body weight in individuals with obesity.
    Halseth A; Shan K; Walsh B; Gilder K; Fujioka K
    Obesity (Silver Spring); 2017 Feb; 25(2):338-345. PubMed ID: 28026920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors: A Randomized Clinical Trial.
    Nissen SE; Wolski KE; Prcela L; Wadden T; Buse JB; Bakris G; Perez A; Smith SR
    JAMA; 2016 Mar; 315(10):990-1004. PubMed ID: 26954408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Naltrexone/bupropion: an investigational combination for weight loss and maintenance.
    Makowski CT; Gwinn KM; Hurren KM
    Obes Facts; 2011; 4(6):489-94. PubMed ID: 22249001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bupropion-SR plus naltrexone-SR for the treatment of mild-to-moderate obesity.
    Ali KF; Shukla AP; Aronne LJ
    Expert Rev Clin Pharmacol; 2016; 9(1):27-34. PubMed ID: 26512740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug safety evaluation of naltrexone/bupropion for the treatment of obesity.
    Verpeut JL; Bello NT
    Expert Opin Drug Saf; 2014 Jun; 13(6):831-41. PubMed ID: 24766397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ACS chemical neuroscience molecule spotlight on contrave.
    Mercer SL
    ACS Chem Neurosci; 2011 Sep; 2(9):484-6. PubMed ID: 22860172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes.
    Hollander P; Gupta AK; Plodkowski R; Greenway F; Bays H; Burns C; Klassen P; Fujioka K;
    Diabetes Care; 2013 Dec; 36(12):4022-9. PubMed ID: 24144653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term effects of weight-reducing drugs in people with hypertension.
    Siebenhofer A; Winterholer S; Jeitler K; Horvath K; Berghold A; Krenn C; Semlitsch T
    Cochrane Database Syst Rev; 2021 Jan; 1(1):CD007654. PubMed ID: 33454957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Naltrexone extended-release plus bupropion extended-release for treatment of obesity.
    Yanovski SZ; Yanovski JA
    JAMA; 2015 Mar 24-31; 313(12):1213-4. PubMed ID: 25803343
    [No Abstract]   [Full Text] [Related]  

  • 17. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial.
    Wadden TA; Foreyt JP; Foster GD; Hill JO; Klein S; O'Neil PM; Perri MG; Pi-Sunyer FX; Rock CL; Erickson JS; Maier HN; Kim DD; Dunayevich E
    Obesity (Silver Spring); 2011 Jan; 19(1):110-20. PubMed ID: 20559296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Psychiatric Safety and Weight Loss Efficacy of Naltrexone/bupropion as Add-on to Antidepressant Therapy in Patients with Obesity or Overweight.
    McIntyre RS; Paron E; Burrows M; Blavignac J; Gould E; Camacho F; Barakat M
    J Affect Disord; 2021 Jun; 289():167-176. PubMed ID: 33989969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The relationship between early weight loss and weight loss at 1 year with naltrexone ER/bupropion ER combination therapy.
    Fujioka K; Plodkowski R; O'Neil PM; Gilder K; Walsh B; Greenway FL
    Int J Obes (Lond); 2016 Sep; 40(9):1369-75. PubMed ID: 27328752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contrave--a combination of bupropion and naltrexone for weight loss.
    Med Lett Drugs Ther; 2014 Nov; 56(1455):112-4. PubMed ID: 25372849
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.